Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jul:500:117375.
doi: 10.1016/j.taap.2025.117375. Epub 2025 May 6.

Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation

Joshua J Deppas  1 , Brian F Kiesel  1 , Jianxia Guo  2 , Lora H Rigatti  3 , Joseph D Latoche  4 , Anthony Green  5 , Paul Knizner  5 , D Andy Clump  6 , Pinakin Pandya  6 , Frank P Vendetti  6 , Christopher J Bakkenist  7 , Jan H Beumer  8
Affiliations
Comparative Study

Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation

Joshua J Deppas et al. Toxicol Appl Pharmacol. 2025 Jul.

Abstract

Ionizing radiation (IR) induces damage in the form of DNA strand breaks. As an apical initiator of the DNA damage response, Ataxia telangiectasia and Rad3-related (ATR) mitigates DNA damage, limiting therapeutic efficacy. Small molecule ATR inhibitors (ATRi) restrict this effect and sensitize cancer cells to radiation-induced damage. However, the impact of ATR inhibition in non-malignant tissues following IR is currently unknown. Here, we document the impact of ATRi on murine toxicity profiles following total body irradiation (TBI). Mice were stratified to receive single-dose ATRi (ceralasertib, elimusertib, or berzosertib), 6 Gy TBI, or the combination. Mice were euthanized 48 h post TBI. Blood and tissues were collected for analysis of complete blood counts and histopathology. To further distinguish toxicity profiles, IC50 values were compared between ATRi. Pharmacokinetics (PK) and pharmacodynamics (PD) were considered as potential explanatory factors of differences in toxicity profiles. Elimusertib was determined to be the most potent ATRi, and ceralasertib the least. We observed neutrophilia with all ATRi. We found that ATRi did not exacerbate any TBI-induced toxicities in mice. Berzosertib presented a unique profile among all ATRi across several toxicity endpoints, including modest amelioration of TBI-associated effects on spleen and lymphocyte and white blood cell counts. Cardiotoxicity was observed following single-dose ceralasertib, but no other ATRi, possibly due to high unbound plasma drug concentrations. Our results further support and guide clinical development of ATRi in clinic.

Keywords: ATR Inhibitor; Berzosertib; Ceralasertib; Elimusertib; Pathology; Radiation; Toxicity.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jan Beumer reports financial support was provided by Commonwealth of Pennsylvania. Jan Beumer reports financial support was provided by National Institutes of Health National Cancer Institute. Jan Beumer reports a relationship with Astra Zeneca that includes: employment of spouse. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

See all similar articles

Cited by

References

    1. Berges A, Cheung A, Pierce A, Dean E, Felicetti B, Standifer N, Smith S, Yates J, Lau A, Stephens C, Krebs M, Harrington K, Hollingsworth S, 2018. Abstract CT118: PK-Biomarker-Safety modelling aids choice of recommended Phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Research 78, CT118–CT118.
    1. Bhatia A, Chen Z, Bruce J, Steuer CE, Zandberg DP, Riess JW, Mitchell D, Davis TH, Patel M, Kaur V, Arnold S, Owonikoko TK, 2022. 656MO Phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma. Annals of Oncology 33, S842.
    1. Ciccia A, Elledge SJ, 2010. The DNA damage response: making it safe to play with knives. Mol Cell 40, 179–204. - PMC - PubMed
    1. Citrin DE, 2017. Recent Developments in Radiotherapy. N Engl J Med 377, 1065–1075. - PubMed
    1. Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN, 2015. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 33, 1060–1066. - PubMed

Publication types